Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hookworm vaccines: past, present, and future.

Alex Loukas1, Jeffrey Bethony, Simon Brooker

  • 1Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Australia. alex.loukas@qimr.edu.au

The Lancet. Infectious Diseases
|October 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptional profiling of the Crocodylus porosus liver cell response to Kunjin virus reveal novel insights into the host-virus interface.

Microbial pathogenesis·2026
Same author

A novel hookworm vaccine candidate identified through immunomic profiling of human protective immunity.

International journal for parasitology·2026
Same author

Transgenic hookworm secretes anti-tetrodotoxin human single chain antibody.

Nature communications·2026
Same author

Advances in vaccine development through the controlled human infection models for hookworm and schistosomiasis.

PLoS neglected tropical diseases·2026
Same author

Optimized hookworm-derived biologic, AIP-2<sub>NTQ48</sub> restores mucosal tolerance and down-regulates colon cancer-associated gene expression in TNBS-induced colitis.

Mucosal immunology·2026
Same author

Functional characterization of secreted Schistosoma mansoni serpin SmSPI reveals factor XIIa inhibition as evidenced by biochemical and human plasma assays and supported by AI-assisted structural modeling.

International journal for parasitology·2026
Same journal

Nine-valent human papillomavirus vaccine: implications for cervical elimination.

The Lancet. Infectious diseases·2026
Same journal

Community-engaged implementation strategies to increase doxycycline post-exposure prophylaxis uptake among men who have sex with men in China (DoxyForward): a three-group, open-label, randomised controlled trial.

The Lancet. Infectious diseases·2026
Same journal

Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.

The Lancet. Infectious diseases·2026
Same journal

Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial.

The Lancet. Infectious diseases·2026
Same journal

Size of the 2026 Ebola outbreak and risk of cross-border spillover from Bundibugyo virus in Ituri Province, DR Congo, and its implications for preparedness: a recalibrated stochastic modelling study.

The Lancet. Infectious diseases·2026
Same journal

Can stochastic modelling predict cross-border spread of the Bundibugyo Ebola virus outbreak in Africa?

The Lancet. Infectious diseases·2026
See all related articles

Developing a hookworm vaccine is crucial for public health, as current treatments are insufficient. Research is progressing, with candidate antigens in clinical trials to combat this widespread parasitic infection.

Area of Science:

  • Parasitology
  • Vaccinology
  • Public Health

Background:

  • Hookworm infections affect nearly a billion people globally, primarily in developing nations.
  • The main health consequence is iron-deficiency anemia due to intestinal blood loss from the parasite.
  • Current treatments fail to control hookworm effectively and reinfection is common.

Purpose of the Study:

  • To explore the development of a prophylactic vaccine against human hookworm infection.
  • To identify potential protective mechanisms and candidate antigens for a hookworm vaccine.
  • To outline a roadmap for vaccine development, considering challenges in low-income regions.

Main Methods:

  • Reviewing previous successes in developing vaccines for canine hookworm.
  • Analyzing laboratory and field studies on human anti-hookworm vaccine candidates.

Related Experiment Videos

  • Examining vaccine development strategies for other blood-feeding nematodes.

    • Main Results:

    • Several candidate antigens have been identified, with one currently in clinical trials.
    • The feasibility of a hookworm vaccine is supported by prior successes in veterinary medicine.
    • Recombinant vaccines for parasitic nematodes remain an area for development.

    Conclusions:

    • A prophylactic hookworm vaccine offers a promising complementary strategy for disease control.
    • Addressing challenges in developing countries, including the lack of a commercial market, is essential.
    • Continued research and development are needed to bring a human hookworm vaccine to fruition.